

WHEN ALZHEIMER'S TREATMENTS ARRIVE, HOW PREPARED WILL JAPAN BE TO MEET DEMAND?


AN ASSESSMENT OF JAPAN'S HEALTH CARE INFRASTRUCTURE

Early intervention is the key

All evidence suggests that Alzheimer's disease must be treated in its early stages to prevent the progression to full-blown dementia. There is hope that one or more drug therapies with that effect may become available by 2023. However, preventive treatment of Alzheimer's disease implies a complex patient journey. At that point, a complex patient journey will start—sending those over the age of 50 on a four-part path, involving various specialists with multiple appointments at different facilities, to:

1. **Screen** for mild cognitive impairment (MCI).
2. **Evaluate** for potential Alzheimer's disease.
3. **Test** for signs of brain pathology.
4. **Treat** with intravenous (IV) infusion therapy.

Ideally, this process would happen as quickly as possible to prevent progression, but is Japan's healthcare system ready? Projections based on a simulation model suggest otherwise.



Millions of patients would need to be seen


Of the 51.6 million people 50 years and older who are eligible

31 MILLION
WOULD GET SCREENED IN A DOCTOR'S OFFICE




7.7 million who screen positive for MCI

3.9 MILLION
WOULD SEE A DEMENTIA SPECIALIST FOR EVALUATION



Wait lists might be extensive



Increased capacity could avoid unnecessary disease progression

With enough capacity for Aβ testing and treatment an additional

121,000
PEOPLE WOULD NOT DEVELOP ALZHEIMER'S DEMENTIA



With enough capacity for all aspects of care (diagnosis by specialist, Aβ testing, and treatment) an additional

616,000
PEOPLE WOULD NOT DEVELOP ALZHEIMER'S DEMENTIA

Action is needed to reduce capacity constraints

- » TRAIN MORE PROVIDERS IN DEMENTIA CARE AND DEVELOP TOOLS TO MAKE THEM MORE EFFICIENT.
- » EXPAND USE OF CSF TESTING FOR BIOMARKERS.
- » UTILIZE ALL OPTIONS FOR INFUSION THERAPY, INCLUDING THE HOME SETTING.
- » ENSURE APPROPRIATE COVERAGE OF SERVICES AND TESTS.